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Background: Endotoxins stimulate T helper 1 cell maturation and send a negative signal to T helper 2 polarisation.
This causes a decrease IgE levels and prevents atopy (Hygiene hypothesis). It is shown that this response is under
genetic control by polymorphisms in CD14 and TLR4 genes in some researchs. We aimed to investigate the
effects of genetic variants of CD14 (−) and TLR4 (Asp299Gly, Thr399Ile) genes on asthma phenotypes in adults
with asthma.
Methods: Asthma patients (n = 131) and healthy control cases (n = 75) were included in the study. Relations between
CD14 C-159 T, TLR4 299 and TLR4 399 genotypes and duration of asthma history of allergic rhinitis-dermatitis, total
IgE, eosinophil, skin prick test, forced expiratory volume 1 (FEV1) and severity of disease were evaluated. Real time PCR
(RT-PCR) was used for genotyping.
Results: For CD14-159, presence of the C allele (CC + CT) was more frequent among those with low median log
(logarithm) IgE levels, but no statistically significant difference in all asthma group (p = 0.09). C allele was significantly
correlated with low total IgE levels and T allele with high total IgE levels in atopics (p = 0.04). CC + CT genotype was
more frequent in moderate and severe asthma group in atopics (p = 0.049). TLR4 299 and TLR4 399 genotypes and
asthma phenotypes were not found to be significantly correlated (p > 0.05).
Conclusions: Total IgE levels were found to be low among patients with the CC + CT genotype, and high among
patients with the TT genotype contrary to the results of many other studies, which is therefore an important finding.
Another important finding was that the C allele is a risk factor for moderate and severe asthma.
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Asthma is a complex disease in which pathogenesis is
related to both genetic and environmental factors [1]. In
1989, Strachan [2] put “hygiene hypothesis”, which pro-
posed that reduced exposure to infectious microorgan-
isms in childhood leads to an increased risk of allergic
disease in later years. It is thought that bacteria stimulate
T helper 1 (Th1) maturation, inhibite T helper 2 (Th2)
polarisation and ultimately decrease IgE levels. Innate
immunity utilizes the Toll-like receptor (TLR) family to
identify pathogens. TLRs are expressed on the cell* Correspondence: fusunsahin19700@hotmail.com
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reproduction in any medium, provided the orsurface and initiate immune defence by recognising
structures specific to microorganisms, such as lipopoly-
saccharide (LPS) [3]. Pathogens also contain complexes
called “pathogen associated molecular patterns (PAMPs)”,
which are not present in the host [4]. During an infection,
macrophages recognise PAMPs via TLRs. Dendritic cell
activation occurs due to the stimulation of TLRs, enabling
communication between peripheral and lymphatic tissues;
in turn T cells are activated, which is the most important
component of the acquired immune system [5,6]. Numer-
ous studies have implicated TLR2, TLR4 and TLR9 in
the pathogenesis of asthma or atopy [7-9]. CD14 is a
multifunctional receptor on macrophages and monocytes
that binds endotoxin and other bacterial wall com-
ponents. CD14 promotes immune activation by facilitatingtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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interleukin-(IL)-12 and IL-18 signalling and interferon-
gamma production. As a result a shift to Th1 occurs and
atopy is prevented. In recent years it was shown that this
response is under genetic control and is specifically deter-
mined by polymorphisms in the CD14. The TLR4 single
nucleotide polymorphisms A896G and C1196T (result in
the amino acid substitutions Asp299Gly→RefSNP ID:
rs4986790 and Thr399Ile→RefSNP ID: rs4986791, re-
spectively) and affect the extracellular domain of the TLR4
receptor [7,11]. These two polymorphisms modify the re-
ceptor’s response to endotoxin, which is an important trig-
ger of asthma [7]. Similarly, the CD14 polymorphism C-
159 T (RefSNP ID: rs2569190) has been shown to influence
serum IgE levels and skin prick test responses to allergens
[7,12]. Allergic disease may emerge through exposure to
endotoxins, although responsiveness may differ according
to genetic factors [11,12]. In this way the effect of endo-
toxins may vary according to the atopic condition of the
host. As a result it is thought that the effect of the CD14
-159 genotype (CC, TT or CT) on the asthma phenotype
(in terms of total IgE levels) may also vary and numerous
studies have been conducted to investigate the relationship
between CD14 variants and total IgE levels [13]. In the
present study, we investigated the effects of genetic variants
of the CD14(C-159 T) and TLR4 (Asp299Gly and
Thr399Ile) polymorphisms on adult asthma phenotypes
specifically the severity of disease, total IgE concentrations
and eosinophil counts. This study is important because it is
the first to evaluate together with the effects of both CD14




Patients with asthma (n = 131) and healthy controls
(n = 75) who presented to the Third Chest Diseases Out-
patient Clinic at the Yedikule Chest Diseases and
Surgery Training and Research Hospital between January
2010 and December 2011 were included in this study. A
power analysis was performed for each gene polymorph-
ism (CD14 -159, TLR4 299, TLR4 399) at the beginning
of the study (to determine the necessary sample size).
We determined the allele frequencies of all polymor-
phisms (CD14 -159, TLR4 299, TLR4 399) according to
the results of the studies from our region [13,14] and a
meta-analysis (that included European, East Asian and
Indian populations) [15]. The allele frequency of CD14
C-159 T was approximately 75% in the asthma group,
53% in the control group. The power analysis was per-
formed according to these values. For the C-159 T poly-
morphism, the required sample size was 74 for each
group (Approximate Test). The allele frequencies for
TLR4 299 and TLR4 399 were approximately 20% in theasthma group, 5% in the control group, an again the reg-
uired sample size was determined to be 70 for each
group (Approximate Test). The number of patients in
our study met these criteria.
Asthma was diagnosed according to the Global Initia-
tive for Asthma (GINA) guidelines in patients with re-
current dyspnoea, wheezing attacks and positive airway
reversibility test (12% or > 200 mL increase in FEV1 after
400 μg salbutamol inhalation) [16]. Patients who had an
attack in the previous month and/or were treated with
systemic steroids, took specific allergen immunotherapy,
had a personal or family history of tuberculosis, or had
active pathology or sequelae upon chest X-ray examin-
ation were excluded. The control group was composed
of healthy individuals with no personal or family history
of atopy or tuberculosis. Ninety six patients with allergic
symptoms or a history of allergy and who showed a posi-
tive reaction to at least one allergen on skin prick testing
were classified as having atopic asthma, and 35 patients
with no allergic symptoms, no personal history and
negative skin test results were classified as having non-
atopic asthma. This study was performed in accordance
with the principles of the Declaration of Helsinki (2008)
and approved by the ethics committee of Yeditepe Uni-
versity. Written and signed informed consent was ob-
tained from all participants.
Measurements
Spirometric evaluations were performed with a
MasterScope-PC (Jaeger, Germany), total IgE levels were
measured with a Unicel D × I 800 analyser (Beckman
Coulter, (US) and eosinophil counts were determined
using an ABX Pentra 120 system (Impedance&Optical,
Minnesota, USA). All patients with asthma underwent
a skin prick test with 15 standard aero-allergens and
five food allergens (ALK-Abellò, Hørsholm, Denmark).
Oedema of >3 mm was accepted as positive.
Genotyping
A total of 131 EDTA containing blood samples were col-
lected from patients with asthma and stored at −80°C
until nucleic acid purification. Residual EDTA contain-
ing blood samples collected for routine biochemistry
tests were used as the control group. Nucleic acids were
isolated from these samples using a commercial genomic
DNA extraction kit (Thermo Scientific, MA, USA).
The Rotor-Gene Q 5plex high resolution melting
(HRM) platform and Rotor-Gene 6000 series software
v1.7 (Qiagen, Hilden, Germany) were used for real time
PCR amplification and HRM analysis. 5x Hot Fire Pol
Evagreen HRM mix (Solis BioDyne, Tartu, Estonia) used
for PCR amplification and PCR reactions were per-
formed in a 20 μL final volume containing 5 μL of puri-
fied genomic DNA. 0.1 mM of primers (Table 1) used
Table 1 Primers used in this study
Primer name Sequence References
TLR_299_F TGA AGA ATT CCG ATT AGC
ATA CTT AGA
[17]
TLR_299_R CTT TCA ATA GTC ACA CTC
ACC AG
In this study
TLR_399_F TGA GTT TCA AAG GTT GCT
GTT CTC
[17]
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10 minutes for initial denaturation followed by 30 cycles
at 95°C for 10 seconds, 53°C for 45 seconds and 72°C
for 45 seconds. After amplification, denaturation was
performed from 72°C to 90°C for HRM analysis. Repre-
sentative samples of genotypes were confirmed by DNATable 2 Characteristics of asthma and control groups























Skin prick test (Asthma)
Positive 96
Negative 35
FEV1: Forced expiratory volume 1.sequencing for TLR4 polymorphisms and via the restric-
tion fragment length polymorphism (RFLP) method for
the CD14 polymorphism. Representative samples were
also used controls for further tests (Table 1) [14,17].
Statistical analysis
Statistical analyses were performed using the SPSS 16
package software (SPSS Inc., Chicago, IL, USA). Patient
demographics and disease characteristics were sum-
marised using descriptive statistics. All numeric data
were expressed as the mean ± standard deviation, and
non-numeric data as frequencies and percentages. Statis-
tical differences between group means were analysed
using Student’s t-test. One- way analysis of variance
(ANOVA) was used to compare means among more
than two groups, and Tukey’s HSD test was used in the
post-hoc analysis as necessary. A chi-square test was
used to determine whether allele and genotype frequen-
cies in the asthma and healthy control groups deviated
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was accepted as statistically significant.
Results
Characteristics of the asthma and control groups are
shown in Table 2. No significant differences were ob-
served among the CD14 -159, TLR4 299, and TLR4 399
genotype distributions between the asthma and control
groups (p > 0.05). The allele and genetic variant frequen-
cies of the two groups are given in Table 3. CD14 C-
159 T, TLR4 299 and TLR4 399 genotypes, total IgE
levels, eosinophil counts, and FEV1 were evaluated ac-
cording to severity of disease and atopy status (Tables 4
and 5). To determine factors affecting total IgE levels,
we performed a logistic regression analysis using the
backward stepwise method for variable selection based
on the likelihood ratio. Because the median IgE level in
the asthmatic patients was 98 kU/L, this value was used
as the threshold for calculations in the logistic regression
analysis (Table 6). A significant correlation was found
between IgE levels and allergic dermatitis, eosinophil
counts, and skin prick test results.
Total IgE levels were converted to a normal distribution
using logarithmic (log) transformation. No significant dif-
ference was observed when individually comparing the
median log IgE (according to 1.99) among patients with
the CC, CT, TT genotypes of the CD14C-159 T poly-
morphism (p = 0.08); in the asthma group, presence of the








CC 26 (19.3) 15 (19.4) 0.99 (NS)*
CT 63 (49.2) 36 (49.2)
TT 42 (31.5) 24 (31.4)
CC + CT (C allele) 115(43.9) 66 (44)
TT (T allele) 147(56.1) 84 (56)
TLR4 299
AA 122 (93.1) 71 (94.7) 0.77 (NS)*
GA 9 (6.9) 4 (5.3)
A allele 253 (96.6) 146 (97.3)
G allele 9 (3.4) 4 (2.7)
TLR4 399
CC 120 (91.6) 71 (94.7) 0.58 (NS)*
CT 11 (8.4) 4 (5.3)
C allele 251 (95.8) 146 (97.3)
T allele 11 (4.2) 4 (2.7)
NS: Not significant.
*Chi-square test.low IgE levels, but no statistically significant difference
was detected (p = 0.09, Figure 1A). Patients in the asthma
group were classified as either atopic and non-atopic ac-
cording to the results of the skin prick test and history of
atopic rhinitis-dermatitis A significant association was ob-
served between skin prick test positivity and high total IgE
levels and eosinophil counts. Moderate asthma was more
frequent in the atopic group and severe asthma was found
in the non-atopic group; FEV1 was lower in both the
atopic and non-atopic groups. In atopic patients, there
was a significant association between the median log IgE
(according to 1.99) and the presence of the C allele (p =
0.04, Figure 1B). As a result, it was found that the C allele
was significantly correlated with low total IgE levels and
that the T allele was significantly correlated with high total
IgE levels. However, among all asthma patients, no signifi-
cant association was observed between the severity of
asthma and CC +TT and TT (p = 0.10, Figure 2A). In the
atopy group, a significant association was also observed
between the severity of asthma and CC + TT and TT ge-
notypes (p = 0.049, Figure 2B). Specifically, the C allele
was significantly more frequent in the moderate and se-
vere asthma groups.
The TLR4 299 and TLR4 399 genotypes were not sig-
nificantly associated with asthma phenotype (p > 0.05).
Heterozygous TLR4 genotypes (TLR4 A896G and TLR4
C1196T polymorphisms) were more frequent in the
moderate asthma group, but this association was not
statistically significant. No significant difference was ob-
served between the atopic and non-atopic groups.
Discussion
The CD14 gene is present in the major susceptibility re-
gion (5q31-33) for atopy and asthma [17,18]. Studies in-
vestigating the relationship between the CD14 gene and
atopy and asthma have revealed conflicting results. First,
Baldini et al. [12] described several single nucleotide poly-
morphisms in the CD14 gene, which is a receptor with
high affinity for LPS. The polymorphisms described were
found to affect the binding affinity for Sp1, -2, and −3
transcription factors at the GC box in vitro, thus altering
the expression of CD14. They also detected a C-T substi-
tution in the promoter region of the gene (the CD14-
159 T polymorphism) and higher CD14 levels and low
skin test sensitivity in TT homozygotes [12]. The CD14
C-159 T polymorphism involves a C→ T nucleotide sub-
stitution, located −260 bp from the translation start site
and −159 bp from the transcription start site, which alters
CD14 promoter activity in vitro by decreasing the affinity
of Sp protein binding and thus enhancing transcriptional
activity [19]. As a result, the CD14 C-159 T promoter
polymorphism was associated with serum CD14 levels
[12,20] as well as the phenotypes of patients with allergy
[18,21]. In a meta-analysis reviewing studies of Asian
Table 4 Genotypic- phenotypic features in all asthma patients with mild, moderate and severe asthma
All asthma patients p Atopic Non-atopic p
(Standart deviation) Asthmatics (Standart deviation) Asthmatics (Standart deviation)
1 2 3 (n = 96) (n = 35)
(n = 19) (n = 78) (n = 34)
FEV1 (%) 88 72 51 <0.001 71 62 <0.001
(6.7) (4.2) (6.2) (12) (13)
Eosinophil (%) 3.25 4.02 3.61 <0.001 3.84 2.2 0.008
(3) (3.35) (2.5) (3.2) (1.3)
Total IgE (kU/L) 170 240 199 0.006 223 47 <0.001
(156) (255) (244) (240) (37)
Log IgE median 1.9 2.02 1.7 0.006 2.1 1.5 <0.001
(0.5) (0.6) (0.6) (0.5) (0.4)
CD14-159
CC 1 14 5 0.27 20 6 0.62
CT 5 31 7 43 19
TT (T Allele) 9 21 3 33 10
CC+CT (CAllele) 6 45 12 0.10 63 25 0.68
TLR4 299
AA 14 60 14 0.45 88 34 0.44
GA 1 6 1 8 1
TLR4 399
CC 14 58 14 0.23 86 34 0.29
CT 1 8 1 10 1
Comperative Features in Atopic and Non-atopic Asthmatics.
1: Mild asthma; 2: Moderate asthma; 3: Severe asthma. FEV1: Forced expiratory volume 1. Log IgE: Logarithm IgE.
Significant p value is shown with black boldface.
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correlated with decreased atopic asthma risk compared to
CC [15,22]. On the other hand in some studies have re-
ported that the C allele [23] was a risk factor and CC
genotype was found to be correlated with positive skin
prick test [24]. Another meta-analysis reported that
among individuals with TT genotypes exposure to low
levels of endotoxins was protective for asthma, but high
levels of endotoxin increased the risk of asthma. Con-
versely, in individuals carrying the C allele exposure to
high levels of endotoxin had a protective effect [25]. In an-
other study, increasing endotoxin exposure was associated
with a reduced risk of allergic sensitisation but and in-
creased risk of non-atopic wheezing in children with the
CC genotype at position −159 of the CD14 gene [26]. In
our study the distributions of the CD14 genotypes (CC,
CT, TT) did not differ significantly between the asthma
and control groups. Unlike the studies mentioned no sig-
nificant correlation was observed between the CD14 geno-
type and positive skin test, however the CD14 genotype
was correlated with the level of total IgE and severity of
disease. Studies investigating the correlation between total
IgE levels and the CD14 genotype revealed conflictingresults. In one study the CD14-159 genotype was corre-
lated with total IgE levels and this correlation was re-
ported to vary according to varying levels of endotoxin
exposure [27]. In individuals with the CC genotype both
clinical signs of atopic disease and skin test positivity with
high serum IgE levels were encountered more frequently
[18,28,29]. Similarly in a study of children in India the
CD14 C-159 T CC genotype was strongly associated with
atopic asthma and serum IgE [30]. Saçkesen et al. [13] re-
ported that the T allele was correlated with low levels of
total IgE in children with atopic asthma. The association
between C-159 T genotype and allergic sensitisation de-
pends on the level of exposure to endotoxins: TT homo-
zygotes are protected at low levels of exposure and at risk
at high levels [29]. These findings suggest an antagonistic
interaction between the environment and C-159 T as a de-
terminant of allergic sensitization: the T allele could be ei-
ther a protective factor or a risk factor, depending on the
degree of exposure to environmental microbial products
[29]. In other studies C-159 T alleles were not found to be
correlated with asthma and atopy (e.g.allergic rhinitis) in
children and adults [31-34]. In a study no correlation be-
tween C-159 T and serum IgE levels was found [35].
Table 5 Genotypic-phenotypic features in atopic and non-atopic patients with mild, moderate and severe asthma
Atopic asthmatics p Non-atopic asthmatics p
(Standart deviation) (Standart deviation)
1 2 3 1 2 3
(n = 15) (n = 66) (n = 15) (n = 4) (n = 12) (n = 19)
FEV1 (%) 88 72 51 <0.001 89 69 52 0.03
(6.7) (4.2) (6.2) (4.4) (5.1) (4.9)
Eosinophil (%) 3.25 4.02 3.61 0.73 1.50 1.93 2.43 0.46
(3) (3.35) (2.5) (0.6) (1.2) (1.4)
Total IgE (kU/L) 170 240 199 0.63 63 40 43 0.49
(156) (255) (244) (47) (33) (38)
Log IgE median 2 2.1 2 0.75 1.7 1.4 1.5 0.49
(0.5) (0.5) (0.6) (0.5) (0.5) (0.4)
CD14-159
CC 1 14 5 0.14 1 1 4 0.70
CT 5 31 7 2 7 10
TT (T Allele) 9 21 3 1 4 5
CC + CT (C Allele) 6 45 12 0.049 3 8 14 0.82
TLR4 299
AA 14 60 14 0.92 4 11 19 0.41
GA 1 6 1 - 1 -
TLR4 399
CC 14 58 14 0.70 4 11 19 0.41
CT 1 8 1 - 1 -
1: Mild asthma; 2: Moderate asthma; 3: Severe asthma. FEV1: Forced expiratory volume 1. Log IgE: Logarithm IgE.
Significant p value is shown with black boldface.
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medianlog IgE concentration and asthma group (atopic
and non-atopic) regarding CD14 genotype distribution in
our study, although a significant difference was observed
within the atopic asthma group for median log IgE levelsTable 6 Logistic regression analysis for total IgE level >98
kU/L
Multivariate
OR 95% CI p
Age − − −
Sex − − −
Allergic rhinitis − − −
Allergic dermatitis 8.79 1.81-46.88 0.007
Severity of asthma − − −
Eosinophil (%) 1.54 1.23-1.93 0.0001
Skin-prick test reactivity 4.90 1.64-14.62 0.004
CD14 -159 − − −
TLR4 299 − − −
TLR4 399 − − −
OR: Odds ratio; CI: Confidence intervals. 98 kU/L: Median Total IgE level.
Significant p value is shown with black boldface.in relation to the presence of C and T alleles. In contrast
to the low log IgE levels in patients bearing C alleles, pa-
tients bearing T alleles showed high IgE levels. This result
is important because it contrasts with observations in
studies reporting that the C allele was correlated with high
IgE levels and T allele with low IgE levels. The previously
reported prevalence of the CC + CT genotype compared
to TT genotype in asthma patients with higher total IgE
levels may have resulted from the level of endotoxin ex-
posure as reported in a meta-analysis conducted by Marti-
nez et al. [25]. In other words dominant C or TT allele
homozygosity might have a protective or risk-predictive
role according to the varying degrees (low or high) of
endotoxin and microbial particle exposure [29]. The cor-
relation of CD14 C-159 T genotype with the eosinophil
count in asthma was also investigated. Although two pre-
vious studies reported no correlation [18,36], eosinophil
counts tended to be higher in the CC genotype than in
the TT, [13] and to be more common in patients with
moderate and severe asthma [21]. Also in our study the
correlation between the CD14 genotype and eosinophil
count was not statistically significant. The relationship of
the CD14 C-159 T genotype with the severity of asthma
was also investigated. In some studies the C allele has
Figure 1 The association between median log IgE and CC+CT and TT genotypes in all asthma patients and atopic asthma group.
A-The insignificant association between median log IgE (according to 1.99) and CC + CT and TT genotypes in all asthma patients (p = 0.09).
B-The significant association between median log IgE (according to 1.99) and CC + CT and TT genotypes in atopic asthma group (p = 0.04).
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attacks; whereas the T allele is associated with less severe
asthma [37,38]. The CD14 C allele was found to be more
common in asthma patients who were allergic to house
dust. In addition, exposure of these patients to house dustFigure 2 The association between the severity of asthma and CC+CT
group. A-The insignificant association between the severity of asthma and
B-The significant association between the severity of asthma and CC + CTcaused moderate-severe asthma attacks [39]. Similarly our
study found that the frequency of the C allele was signifi-
cantly higher in the moderate and severe asthma group.
Genetic variations in TLR1, TLR2, TLR4, TLR6 and
TLR10 have been associated with the development ofand TT genotypes in all asthma patients and atopic asthma
CC + CT and TT genotypes in all asthma patients (p = 0.10).
and TT genotypes in atopic asthma group (p = 0.049).
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chromosome 9q33.1 [41]. Polymorphisms of TLR4 genes
are reportedly related to a decreased response to LPS in
humans. Individuals with the Asp299Gly TLR4 poly-
morphism were shown to have decreased IL-12 and IL-
10 levels produced by mononuclear cells stimulated with
LPS and a four-fold higher risk of asthma [42]. In a
study conducted by Saçkesen et al. on heterozygous
Turkish children the TLR4 polymorphism was reported
to be related with mild asthma and may protect against
severe asthma [13]. On the other hand, other studies
have failed to find a correlation between common TLR4
mutations (especially Asp299Gly) and asthma or atopy
[8,41,43,44], the severity of asthma may have been a con-
founding factor in these analyses [41]. Nevertheless
TLR4 polymorphism was more closely related to the
moderate and severe atopic asthma group than the mild
atopic asthma group For the Asp299Gly polymorphism
the Asp allele was associated with mild atopic asthma
and the Gly allele with moderate and severe asthma [8].
Our study did not detect a relationship between the
TLR4 299 or TLR4 399 genetic variants and atopic con-
ditions or asthma , nor did we observe a significant rela-
tionship between these genetic variants and the severity
of asthma.
Conclusions
A statistically significant correlation between CD14 ge-
notypes and total IgE levels and severity of asthma was
found in our atopic patients. Total IgE levels were found
to be low among patients with the CC + CT genotype,
and high among patients with the TT genotype contrary
to the results of many other studies, which is therefore
an important finding. This may be explained by the ex-
posure of atopic asthma patients to varying endotoxin
levels as stated in some study reports. Another import-
ant finding was that the C allele is a risk factor for mod-
erate and severe asthma. Further studies will allow for
the gathering of more detailed information.
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